ChromaDex Corp. (Los Angeles, CA) now has official regulatory authorization to sell its patented nicotinamide riboside chloride (NR), called Niagen, to consumers in the European Union (EU) and Australia. In August of 2019, ChromaDex announced that it had received a positive opinion from the European Food Safety Authority (EFSA) on NR as a novel food ingredient for use in food supplements, at a serving of 300 mg daily, for the healthy adult population. On January 10, 2020 the European Commission officially authorized ChromaDex to sell NR as a novel food.
In December of 2019, ChromaDex announced that it had extended its partnership with Matakana Health (MHL; Auckland, New Zealand), a dietary supplement manufacturer and distributor, until 2023. This partnership expanded distribution to Australia where ChromaDex received approval for NR as an ingredient in listed Complementary Medicines from the Australian Therapeutic Goods Administration. On January 8, 2020, Australian Registry of Therapeutic Goods gave the firm its listing number for Tru Niagen, its branded finished product.
As the regulatory applicants and innovators, ChromaDex will benefit from market exclusivity in Australia until December 2021 and in the EU until February 2025.